New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
18:05 EDTZTSZoetis could climb 25%, Barron's says
Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
News For ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ZTS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use